Compare iShares iBoxx $ High Yield Corporate Bond ETF (HYG) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ High Yield Corporate Bond ETF vs Twist Bioscience Corp — how do they compare? iShares iBoxx $ High Yield Corporate Bond ETF trades at $79.66, while Twist Bioscience Corp trades at $94.58 (market cap $5.45B). The key difference: Twist Bioscience Corp is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| HYG | TWST | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $81.32 | $102.88 |
52-Week Low | $78.72 | $24.16 |
Market Cap | — | $5.45B |
Enterprise Value | — | $5.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HYG trades at $79.68, up slightly by 0.04% today, but technical indicators signal a bearish trend with moving averages and overall signals pointing to selling pressure. The fund has declared dividends for 2026, including $0.37 and $0.41 payouts, amid a backdrop of high bond market volatility and investor caution. Recent news highlights elevated put volume and bearish bets against high-yield bonds, reflecting broader market uncertainty.
The outlook for HYG is cautious due to bearish technicals and macroeconomic headwinds like potential Fed rate hikes. Risks include interest rate sensitivity and inflation pressures, but the dividend yield may attract income-focused investors. Wall Street sentiment is mixed, with institutional flows into bond ETFs offering some support amid prevailing risks.
Twist Bioscience (TWST) trades at $87.41, down 6.86% today, with a bullish technical outlook despite recent earnings misses. The company shows strong revenue growth from $204M in 2022 to $377M in 2025, though it remains unprofitable with a -19.85% net margin. Analyst consensus is strongly bullish with 11 buy ratings and a $91.63 price target, while recent news highlights AI-driven drug discovery collaborations and upcoming Q3 earnings.
The stock presents growth potential through expanding synthetic biology applications and AI partnerships, but carries significant risk from persistent losses, negative cash flow, and high valuation multiples (P/S 13.94). Investors should weigh the company's innovation trajectory against its path to profitability amid competitive biotech pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
